STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #495 by analyst upside · 2026-06-27
RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Market Cap $355M · P/E 0x
ANALYST PRICE TARGET
+188.8%
implied upside to consensus target
Current Price $3.25
Consensus Target $9.39
Bull Target $16.0
Bear Target $3.0
Analysts Covering 11
ANALYST CONSENSUS — HOLD
Strong Buy
0
Buy
5
Hold
5
Sell
1
52-Week Low $2.4
52-Week High $5.45
YTD Return -6.1%
FUNDAMENTALS
Market Cap $355M
P/E Ratio (TTM) N/A
Forward P/E -2.8x
EPS (TTM) $-1.87
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.4
52-Week High $5.45
Current Price $3.25
Bear Target $3.0
Bull Target $16.0
● Now $3.25 ● Target $9.39
TRADING DATA
Avg Volume 3.0M
YTD Return -6.1%
Analyst Count 11
Consensus Hold
Upside to Target +188.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Rocket Pharmaceuticals, Inc. (RCKT) is currently trading at $3.25 with a Wall Street consensus price target of $9.39, implying potential upside of 188.8% over the next 12 months. 11 analysts currently cover RCKT, with a consensus rating of Hold — 45% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $3.0.

RCKT operates in the Healthcare sector with a market capitalisation of $355M. The stock is down 6.1% year-to-date and is currently trading near the lower end of its 52-week range of $2.4 – $5.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RCKT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital — Reiterated
Buy → Buy 2026-05-11 33% win rate (6 calls)
B of A Securities — Reiterated
Buy → Buy 2026-03-30 Building track record
Chardan Capital — Reiterated
Buy → Buy 2026-03-27 33% win rate (6 calls)
Goldman Sachs — Reiterated
Sell → Sell 2026-03-02 Building track record
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-02-27 40% win rate (10 calls)
B of A Securities — Reiterated
Buy → Buy 2025-11-18 Building track record
JP Morgan ↓ Downgrade
Overweight → Underweight 2025-11-18 43% win rate (7 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-10-14 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →